Science
The Science Behind Your Care.
Research in Development
AI Innovation Grounded in Real Clinical Data.
Published Research
A multifaceted approach for obstructive sleep apnea classification from ECG signal using deep learning. npj Biological Timing and Sleep, 2026. KardioStatus-supported ECG deep-learning research, co-authored by Dr. Antony Chu. This study concerns sleep apnea; it is not a study of peptide response.
Read the patient summary and development statusYour Options
Understand the Options in Your Care Plan.
GLP-1 Medications
Gut-hormone peptide medications, such as semaglutide and tirzepatide, that slow gastric emptying and reduce appetite.
BPC-157
Studied for soft-tissue and gut repair. Human evidence is limited; much of the research is preclinical.
CJC-1295 / Ipamorelin
Growth-hormone secretagogues. Human evidence for effects on sleep and lean mass is limited, and IGF-1 monitoring is required.
NAD+
A cellular cofactor in energy metabolism, given by injection or infusion. Human evidence for supplementation is limited.
Laboratory Testing and Wearable Trends
Not a drug, but central to every plan: how we establish a baseline and see whether a plan is working.
Peptide Research, Summarized Honestly
What the Published Research Shows About Our Peptides.
Vasireddi et al., HSS Journal, 2025
BPC-157 in Orthopaedic Sports Medicine
A systematic review of 36 studies: 35 preclinical and 1 clinical. Promising animal healing data, no clinical safety data.
Read the Source ↗Pickart and Margolina, IJMS, 2018
GHK-Cu and Gene Expression
A review of mostly laboratory work on collagen, blood vessel growth and gene regulation. The 2026 systematic review adds that human trials remain small.
Read the Source ↗Goldstein et al., 2012; McGuire et al., 2026 (preprint)
Thymosin Beta-4 and TB-500
Thymosin beta-4 is studied in skin, eye, heart and nervous-system repair. Only one of 80 studies in a 2026 scoping review directly evaluated TB-500.
Read the Source ↗Dalmasso et al., Gastroenterology, 2008
KPV and Intestinal Inflammation
In human cell lines and two mouse models, KPV reduced inflammatory signaling and colitis. It has not been tested in people.
Read the Source ↗See how these apply to each combination on the peptide stack pages.
Evidence and Safety
Understand the Evidence and Treatment Status.
The medication itself is FDA-approved and dispensed as a standard product. Approval is specific to labeled indications; other uses are clinician-directed.
The active molecule may be FDA-approved in a branded product, but this compounded preparation is made for you individually and is not itself FDA-approved or evaluated for safety, effectiveness or quality.
Included on FDA's interim Category 1 list for compounding. That is a compounding-policy classification, not an approval and not proof of efficacy.
FDA has flagged this substance on its Category 2 safety-risk review list. We treat it as a monitored, investigational option, not an "approved" peptide, and advisory-committee recommendations on it are non-binding.
Human evidence is limited; much of the research is preclinical or early-stage, or drawn from off-label use of an approved molecule. We say so before you start, not after.
503A Category 1: Under Evaluation
GHK-Cu appears on FDA’s May 14, 2026 Category 1 list except injectable routes. Category 1 is an interim compounding-policy classification, not FDA approval and not proof of efficacy. Other Category 1 substances include glutathione, NAD/NADH, L-citrulline, creatine monohydrate and alpha-lipoic acid; not all are peptides.
Category 2 and Recent PCAC Review
FDA’s Category 2 safety-risk page includes or has included peptide-related substances such as MOTS-c, BPC-157, KPV, TB-500, Semax, Epitalon, emideltide (DSIP), ipamorelin, GHRP-2/6 and Kisspeptin-10. FDA’s July 2026 briefing proposed not including the reviewed substances on the 503A Bulks List; advisory-committee recommendations are non-binding. SOVRYN presents these as monitored investigational candidates, not as “approved” peptides.
Sources: FDA 503A Category list (May 14, 2026); FDA Category 2 safety-risk page; FDA July 23–24, 2026 PCAC materials. This page describes SOVRYN’s clinical approach and is not a treatment recommendation.
How We Label Content
Four Labels, So You Know What You Are Reading.
Published research
Peer-reviewed work, cited with its source.
SOVRYN clinical protocol
How our clinicians apply the evidence, with a named reviewer and date.
Clinical perspective
Informed commentary from a named clinician.
Research in development
Work that is not yet validated or available as a service.
A white paper is not automatically peer-reviewed and does not validate a predictive tool. Read The SOVRYN Standard for the questions we think you should ask any peptide provider, or browse the protocols and white papers.
Questions About the Evidence? Ask a Clinician
Ten minutes, no card, reviewed by a clinician.